Abstract Chronic musculoskeletal pa

Abstract Chronic musculoskeletal pain is a major—and
growing—burden on today’s ageing populations. Professional
organisations including the American College of
Rheumatology (ACR), American Pain Society (APS) and
European League Against Rheumatism (EULAR) have
published treatment guidelines within the past 5 years to
assist clinicians achieve effective pain management. Safety
is a core concern in all these guidelines, especially for
chronic conditions such as osteoarthritis that require longterm
treatment. Hence, there is a consensus among recommendations
that paracetamol should be the first-line
analgesic agent due to its favourable side effect and safety
profile, despite being somewhat less effective in pain
relief than anti-inflammatory drugs. Cyclooxygenase-2
(COX-2)-selective anti-inflammatory drugs were developed
with the goal of delivering effective pain relief
without the serious gastrointestinal (GI) side effects linked
with traditional non-selective non-steroidal anti-inflammatory
drugs (NSAIDs). Clinical trial evidence supported
these benefits, and COX-2 inhibitors were widely adopted,
both in clinical practice and in official guidelines. Recently,
accumulating data have linked COX-2 inhibitors with
serious cardiovascular and/or cardiorenal effects and/or
serious cutaneous adverse reactions (SCARs), particularly
at anti-inflammatory doses or when used long term.
Regulatory authorities in both Europe and the USA have
responded to these data with the withdrawal of rofecoxib
and valdecoxib, and the strengthening of prescribing
advice on all anti-inflammatory drugs. COX-2 inhibitors
and non-selective NSAIDs should now be used with
increased caution in patients at increased cardiovascular
and/or cardiorenal risk, e.g., patients with congestive heart
failure, hypertension, etc. Regulatory advice and good

ผลลัพธ์ (อังกฤษ) 2:

Abstract Chronic Musculoskeletal Pain is a Major-and
-Growing burden on today's aging populations. Professional
organizations including The American College of
Rheumatology (ACR), American Pain Society (APS) and
European League Against Rheumatism (EULAR) Have
Published guidelines Treatment Within The past 5 years to
Assist clinicians Achieve Effective Pain Management. Safety
is a core Concern in all these guidelines, especially for
chronic conditions that Require longterm Such As Osteoarthritis
Treatment. Hence, there is a consensus Among recommendations
that should be PARACETAMOL The First-Line
analgesic Agent Due to safety and ITS Favourable Side Effect
Profile, Despite being in Pain Effective Somewhat less
than Anti-inflammatory Drugs RELIEF. Cyclooxygenase-2
(COX-2) -selective Anti-inflammatory Drugs were developed
with The Goal of RELIEF Delivering Effective Pain
Without The Serious gastrointestinal (GI) Side effects linked
with Traditional non-Selective non-steroidal Anti-inflammatory
Drugs (NSAIDs). Clinical Trial Evidence Supported
Benefits these, and COX-2 inhibitors were widely adopted,
Both in Clinical Practice and in Official guidelines. Recently,
accumulating Data Have linked COX-2 inhibitors with
Serious Cardiovascular and / or Cardiorenal effects and / or
Serious cutaneous adverse reactions (Scars), particularly
at Anti-inflammatory doses or When Used long term.
Regulatory authorities in Both Europe and The USA Have.
responded to these Data with The withdrawal of rofecoxib
and valdecoxib, and The strengthening of prescribing
Advice on Anti-inflammatory Drugs all. COX-2 inhibitors
and non-Selective NSAIDs should now be Used with
increased caution in patients at increased Cardiovascular
and / or Cardiorenal risk, eg, patients with congestive Heart
Failure, hypertension, etc. Regulatory Advice and good.